MA29811B1 - [1,3,4]-thiadiazol-2-yl-amides d'acide (aryle bicyclique)-sulfonique procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques - Google Patents

[1,3,4]-thiadiazol-2-yl-amides d'acide (aryle bicyclique)-sulfonique procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques

Info

Publication number
MA29811B1
MA29811B1 MA30789A MA30789A MA29811B1 MA 29811 B1 MA29811 B1 MA 29811B1 MA 30789 A MA30789 A MA 30789A MA 30789 A MA30789 A MA 30789A MA 29811 B1 MA29811 B1 MA 29811B1
Authority
MA
Morocco
Prior art keywords
disorders
thiadiazol
processes
preparation
sulfonic
Prior art date
Application number
MA30789A
Other languages
English (en)
Inventor
Karl Schoenafinger
Stefanie Keil
Matthias Urmann
Hans Matter
Maike Glien
Wolfgang Wendler
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA29811B1 publication Critical patent/MA29811B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

L'INVENTION CONCERNE DES [1,3,4]THIADIAZOL-2-YL-AMIDES BICYCLIQUES DE L'ACIDE ARYL-SULFONIQUE DE FORMULE (I), DANS LAQUELLE LES RADICAUX SONT TELS QUE DÉFINIS, AINSI QUE LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET DÉRIVÉS PHYSIOLOGIQUEMENT FONCTIONNELS QUI PRÉSENTENT UNE ACTIVITÉ AGONISTE PPAR DELTA, ALPHA, ET GAMMA. CETTE INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION DE CES COMPOSÉS. LESDITS COMPOSÉS PEUVENT SERVIR À TRAITER ET/OU PRÉVENIR DES TROUBLES DU MÉTABOLISME DES ACIDES GRAS, DES TROUBLES DE L'UTILISATION DU GLUCOSE, DES TROUBLES IMPLIQUANT LA RÉSISTANCE À L'INSULINE, AINSI QUE DES TROUBLES DE DÉMYÉLINISATION ET D'AUTRES TROUBLES NEURODÉGÉNÉRATIFS DU SYSTÈME NERVEUX CENTRAL ET PÉRIPHÉRIQUE
MA30789A 2005-10-06 2008-03-31 [1,3,4]-thiadiazol-2-yl-amides d'acide (aryle bicyclique)-sulfonique procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques MA29811B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05021785 2005-10-06
PCT/EP2006/009300 WO2007039174A2 (fr) 2005-10-06 2006-09-26 [1,3,4]-thiadiazol-2-yl-amides bicycliques de l'acide aryl-sulfonique, leurs procedes de preparation, et leur utilisation en tant que substances pharmaceutiques

Publications (1)

Publication Number Publication Date
MA29811B1 true MA29811B1 (fr) 2008-09-01

Family

ID=45219048

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30789A MA29811B1 (fr) 2005-10-06 2008-03-31 [1,3,4]-thiadiazol-2-yl-amides d'acide (aryle bicyclique)-sulfonique procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques

Country Status (19)

Country Link
US (2) US7612104B2 (fr)
EP (1) EP1937675B1 (fr)
JP (1) JP2009510146A (fr)
KR (1) KR20080050607A (fr)
CN (1) CN101282969A (fr)
AR (1) AR056563A1 (fr)
AT (1) ATE513829T1 (fr)
AU (1) AU2006299088A1 (fr)
BR (1) BRPI0616872A2 (fr)
CA (1) CA2624329A1 (fr)
IL (1) IL190459A0 (fr)
MA (1) MA29811B1 (fr)
NO (1) NO20081676L (fr)
NZ (1) NZ567204A (fr)
RU (1) RU2008113209A (fr)
TW (1) TW200811120A (fr)
UY (1) UY29848A1 (fr)
WO (1) WO2007039174A2 (fr)
ZA (1) ZA200801989B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201040153A (en) 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted tetrahydronaphthalenes, process for preparation thereof and use thereof as medicaments
UY32442A (es) * 2009-02-13 2010-09-30 Sanofi Aventis Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
EP3986890B1 (fr) 2019-06-18 2023-11-15 Pfizer Inc. Dérivés de benzisoxazole sulfonamide
CN116041230B (zh) * 2023-01-08 2024-03-19 中国海洋大学 一种nlrp3炎症小体抑制剂及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670282B2 (de) * 1967-10-24 1977-02-24 Antidiabetisch wirksame hydrindensulfonylamino-pyrimidine sowie verfahren zu deren herstellung
DE2533605A1 (de) * 1975-07-26 1977-02-03 Bayer Ag Antiparasitenmittel
US5097669A (en) 1991-02-11 1992-03-24 Westinghouse Electric Corp. Control of hydrogen cooler employed in power generators
BR0110428A (pt) * 2000-04-28 2003-06-17 Sankyo Co Composto ou um seu sal farmacologicamente aceitável, composição farmacêutica, usos de um composto ou um seu sal farmacologicamente aceitável, de um modulador de ppar gama e de um antagonista parcial, agentes que inibe a diferenciação de adipócitos, que acentua ou recupera a função osteogênica, para tratamento ou prevenção de osteoporose, que tem atividade moduladora de ppar gama, diminuidor do açúcar no sangue, para tratamento ou prevenção de diabetes melito, e, para tratamento ou prevenção
JP2009513523A (ja) * 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
CN101238109B (zh) 2005-06-09 2011-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的茚满衍生物

Also Published As

Publication number Publication date
US20100022603A1 (en) 2010-01-28
EP1937675B1 (fr) 2011-06-22
CN101282969A (zh) 2008-10-08
UY29848A1 (es) 2007-05-31
EP1937675A2 (fr) 2008-07-02
US7772257B2 (en) 2010-08-10
WO2007039174A3 (fr) 2007-08-09
JP2009510146A (ja) 2009-03-12
WO2007039174A2 (fr) 2007-04-12
IL190459A0 (en) 2008-11-03
NZ567204A (en) 2010-06-25
BRPI0616872A2 (pt) 2011-07-05
RU2008113209A (ru) 2009-10-10
US7612104B2 (en) 2009-11-03
KR20080050607A (ko) 2008-06-09
ATE513829T1 (de) 2011-07-15
NO20081676L (no) 2008-04-29
ZA200801989B (en) 2009-08-26
US20080293780A1 (en) 2008-11-27
AU2006299088A1 (en) 2007-04-12
CA2624329A1 (fr) 2007-04-12
AR056563A1 (es) 2007-10-10
TW200811120A (en) 2008-03-01

Similar Documents

Publication Publication Date Title
MA29807B1 (fr) Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques.
MA29805B1 (fr) Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques
MA30981B1 (fr) Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments
MA29810B1 (fr) 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques
MA30380B1 (fr) Amides heterocycliques destines a une utilisation en tant que produits pharmaceutiques
MA35874B1 (fr) Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA30073B1 (fr) Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine
MA32323B1 (fr) Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques
MA29811B1 (fr) [1,3,4]-thiadiazol-2-yl-amides d'acide (aryle bicyclique)-sulfonique procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques
MA35875B1 (fr) Dérivés d'aza-adamantane et leurs utilisations
TNSN07021A1 (fr) Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA30782B1 (fr) Amides substitues, procede de production et d'utilisation desdits amides
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA32705B1 (fr) Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
MA29379B1 (fr) Derives de pyrrolidine 3,4-substitues pour le traitement de l'hypertension
MA30084B1 (fr) Triazolopyridazines en tant que modulateurs de la tyrosine kinase
MA29809B1 (fr) N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques
MA32688B1 (fr) Composes n-sulfonamido pyrazolyles polycycliques
MA30720B1 (fr) Analogues de 2-phenoxypyrimidinone
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MX2010006647A (es) Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos.
MA29723B1 (fr) Composes